# Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

> **NCT01386970** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 43 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** zidovudine 300mg and lamivudine 150mg as Combivir

## Key facts

- **NCT ID:** NCT01386970
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-07
- **Final completion:** 2010-07
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386970, "Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01386970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*